» Download Public Reports
67 reports
- Company report
- May 2013
- 10 pages
May 2013
... Including on truly new medicines developed to address unmet patient needs. Additionally, generic medicines, which are manufactured to the same standards of safety, quality and efficacy as their originator ...
November 2012
... Ingredient as branded products. At the beginning of the campaign 72% of consumers said they would use a generic medicine and this rose to 77% after the campaign. generic medicines rose 5% as a proportion ...
July 2012
... Of our main corporate products. First of all, the reduction of lercanidipine sales is due mainly to lower volumes sold as a result of generic competition. Direct sales in italy are down by 11 ...
July 2012
... Committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ...
July 2012
... Cardiovascular), atoris (cardiovascular), zyllt (cardiovascular), lorista (cardiovascular), nolpaza (gastro), prenessa (cardiovascular) and lanzul (gastro). In addition to generic drugs, krka also manages ...
June 2012
... To contend with a signifi- cant increase in expenditure on healthcare. Compared with other developed countries there is only a very low generic drug penetra- tion in japan. In 2004, the generics share ...
May 2012
... A definitive agreement to acquire specialty dermatology generics company fougera pharmaceuticals. Under the terms of the agreement, novartis will acquire the business, which is based in melville, new ...